LAMEA Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report By Distribution Channel, By Drug Class, By Disorder Type, By Country and Growth Forecast, 2024 - 2031

The Latin America, Middle East and Africa Diabetic Neuropathy Treatment Market would witness market growth of 9.6% CAGR during the forecast period (2024-2031).

The Brazil market dominated the LAMEA Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $165 million by 2031.The Argentina market is showcasing a CAGR of 10.2% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 9.3% during (2024 - 2031).

Diabetic neuropathy is a serious and debilitating complication of diabetes, affecting millions of people. It is distinguished by nerve damage induced by extended exposure to hyperglycemia. In particular, the hands and feet may experience numbness, pain, and weakness due to this condition.

Moreover, by increasing the likelihood of complications like foot ulcers and amputations and making it challenging to perform daily tasks, diabetic neuropathy can have a substantial negative effect on an individual's quality of life.

Similarly, with more individuals affected by diabetes and at risk of developing diabetic neuropathy, there is a heightened demand for this within Saudi Arabia. According to the International Diabetes Federation, 537 million people have diabetes and 73 million people in the MENA (Middle Esat and North Africa) region by 2045. This will rise to 135.7 million. In 2021, out of a total adult population of 24,194,300 in Saudi Arabia, there were approximately 4,274,100 cases of diabetes in adults, representing a prevalence rate of 17.7%.

Free Valuable Insights: The Worldwide Diabetic Neuropathy Treatment Market is Projected to reach USD 7.4 Billion by 2031, at a CAGR of 7.3%

Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

List of Key Companies Profiled

• Abbott Laboratories
• Eli Lilly And Company
• Pfizer, Inc.
• Lupin Limited
• Astellas Pharma, Inc.
• Glenmark Pharmaceuticals Limited
• Boehringer Ingelheim International GmbH
• Novartis AG
• McKesson Corporation
• GlaxoSmithKline PLC (GSK)

LAMEA Diabetic Neuropathy Treatment Market Report Segmentation

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Others

By Drug Class

• Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
• Antidepressants
• Opioid
• Capsaicin
• Others

By Disorder Type

• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Diabetic Neuropathy Treatment Market, by Distribution Channel
1.4.2 LAMEA Diabetic Neuropathy Treatment Market, by Drug Class
1.4.3 LAMEA Diabetic Neuropathy Treatment Market, by Disorder Type
1.4.4 LAMEA Diabetic Neuropathy Treatment Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis

Chapter 4. LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel
4.1 LAMEA Hospitals Pharmacies Market by Country
4.2 LAMEA Retail Pharmacies Market by Country
4.3 LAMEA Others Market by Country

Chapter 5. LAMEA Diabetic Neuropathy Treatment Market by Drug Class
5.1 LAMEA Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country
5.2 LAMEA Antidepressants Market by Country
5.3 LAMEA Opioid Market by Country
5.4 LAMEA Capsaicin Market by Country
5.5 LAMEA Others Market by Country

Chapter 6. LAMEA Diabetic Neuropathy Treatment Market by Disorder Type
6.1 LAMEA Peripheral Neuropathy Market by Country
6.2 LAMEA Autonomic Neuropathy Market by Country
6.3 LAMEA Proximal Neuropathy Market by Country
6.4 LAMEA Focal Neuropathy Market by Country

Chapter 7. LAMEA Diabetic Neuropathy Treatment Market by Country
7.1 Brazil Diabetic Neuropathy Treatment Market
7.1.1 Brazil Diabetic Neuropathy Treatment Market by Distribution Channel
7.1.2 Brazil Diabetic Neuropathy Treatment Market by Drug Class
7.1.3 Brazil Diabetic Neuropathy Treatment Market by Disorder Type
7.2 Argentina Diabetic Neuropathy Treatment Market
7.2.1 Argentina Diabetic Neuropathy Treatment Market by Distribution Channel
7.2.2 Argentina Diabetic Neuropathy Treatment Market by Drug Class
7.2.3 Argentina Diabetic Neuropathy Treatment Market by Disorder Type
7.3 UAE Diabetic Neuropathy Treatment Market
7.3.1 UAE Diabetic Neuropathy Treatment Market by Distribution Channel
7.3.2 UAE Diabetic Neuropathy Treatment Market by Drug Class
7.3.3 UAE Diabetic Neuropathy Treatment Market by Disorder Type
7.4 Saudi Arabia Diabetic Neuropathy Treatment Market
7.4.1 Saudi Arabia Diabetic Neuropathy Treatment Market by Distribution Channel
7.4.2 Saudi Arabia Diabetic Neuropathy Treatment Market by Drug Class
7.4.3 Saudi Arabia Diabetic Neuropathy Treatment Market by Disorder Type
7.5 South Africa Diabetic Neuropathy Treatment Market
7.5.1 South Africa Diabetic Neuropathy Treatment Market by Distribution Channel
7.5.2 South Africa Diabetic Neuropathy Treatment Market by Drug Class
7.5.3 South Africa Diabetic Neuropathy Treatment Market by Disorder Type
7.6 Nigeria Diabetic Neuropathy Treatment Market
7.6.1 Nigeria Diabetic Neuropathy Treatment Market by Distribution Channel
7.6.2 Nigeria Diabetic Neuropathy Treatment Market by Drug Class
7.6.3 Nigeria Diabetic Neuropathy Treatment Market by Disorder Type
7.7 Rest of LAMEA Diabetic Neuropathy Treatment Market
7.7.1 Rest of LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel
7.7.2 Rest of LAMEA Diabetic Neuropathy Treatment Market by Drug Class
7.7.3 Rest of LAMEA Diabetic Neuropathy Treatment Market by Disorder Type

Chapter 8. Company Profiles
8.1 Abbott Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Acquisition and Mergers:
8.1.5.2 Trial and Approval:
8.1.6 SWOT Analysis
8.2 Eli Lilly And Company
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Acquisition and Mergers:
8.2.6 SWOT Analysis
8.3 Pfizer, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expense
8.3.5 SWOT Analysis
8.4 Lupin Limited
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 SWOT Analysis
8.5 Astellas Pharma, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Glenmark Pharmaceuticals Limited
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 SWOT Analysis
8.7 Boehringer Ingelheim International GmbH
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional & Segmental Analysis
8.7.4 Research & Development Expenses
8.7.5 SWOT Analysis
8.8 Novartis AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.8.6 SWOT Analysis
8.9 McKesson Corporation
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 SWOT Analysis
8.10. GlaxoSmithKline PLC (GSK)
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
8.10.5 SWOT Analysis

TABLE 1 LAMEA Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 2 LAMEA Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 3 LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 4 LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 5 LAMEA Hospitals Pharmacies Market by Country, 2020 - 2023, USD Million
TABLE 6 LAMEA Hospitals Pharmacies Market by Country, 2024 - 2031, USD Million
TABLE 7 LAMEA Retail Pharmacies Market by Country, 2020 - 2023, USD Million
TABLE 8 LAMEA Retail Pharmacies Market by Country, 2024 - 2031, USD Million
TABLE 9 LAMEA Others Market by Country, 2020 - 2023, USD Million
TABLE 10 LAMEA Others Market by Country, 2024 - 2031, USD Million
TABLE 11 LAMEA Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 12 LAMEA Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 13 LAMEA Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country, 2020 - 2023, USD Million
TABLE 14 LAMEA Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country, 2024 - 2031, USD Million
TABLE 15 LAMEA Antidepressants Market by Country, 2020 - 2023, USD Million
TABLE 16 LAMEA Antidepressants Market by Country, 2024 - 2031, USD Million
TABLE 17 LAMEA Opioid Market by Country, 2020 - 2023, USD Million
TABLE 18 LAMEA Opioid Market by Country, 2024 - 2031, USD Million
TABLE 19 LAMEA Capsaicin Market by Country, 2020 - 2023, USD Million
TABLE 20 LAMEA Capsaicin Market by Country, 2024 - 2031, USD Million
TABLE 21 LAMEA Others Market by Country, 2020 - 2023, USD Million
TABLE 22 LAMEA Others Market by Country, 2024 - 2031, USD Million
TABLE 23 LAMEA Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 24 LAMEA Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 25 LAMEA Peripheral Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 26 LAMEA Peripheral Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 27 LAMEA Autonomic Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 28 LAMEA Autonomic Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 29 LAMEA Proximal Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 30 LAMEA Proximal Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 31 LAMEA Focal Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 32 LAMEA Focal Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 33 LAMEA Diabetic Neuropathy Treatment Market by Country, 2020 - 2023, USD Million
TABLE 34 LAMEA Diabetic Neuropathy Treatment Market by Country, 2024 - 2031, USD Million
TABLE 35 Brazil Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 36 Brazil Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 37 Brazil Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 38 Brazil Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 39 Brazil Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 40 Brazil Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 41 Brazil Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 42 Brazil Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 43 Argentina Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 44 Argentina Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 45 Argentina Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 46 Argentina Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 47 Argentina Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 48 Argentina Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 49 Argentina Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 50 Argentina Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 51 UAE Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 52 UAE Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 53 UAE Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 54 UAE Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 55 UAE Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 56 UAE Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 57 UAE Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 58 UAE Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 59 Saudi Arabia Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 60 Saudi Arabia Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 61 Saudi Arabia Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 62 Saudi Arabia Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 63 Saudi Arabia Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 64 Saudi Arabia Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 65 Saudi Arabia Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 66 Saudi Arabia Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 67 South Africa Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 68 South Africa Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 69 South Africa Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 70 South Africa Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 71 South Africa Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 72 South Africa Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 73 South Africa Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 74 South Africa Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 75 Nigeria Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 76 Nigeria Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 77 Nigeria Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 78 Nigeria Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 79 Nigeria Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 80 Nigeria Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 81 Nigeria Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 82 Nigeria Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 83 Rest of LAMEA Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 84 Rest of LAMEA Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 85 Rest of LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 86 Rest of LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 87 Rest of LAMEA Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 88 Rest of LAMEA Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 89 Rest of LAMEA Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 90 Rest of LAMEA Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 91 Key Information – Abbott Laboratories
TABLE 92 Key Information – Eli Lilly And Company
TABLE 93 Key Information – Pfizer, Inc.
TABLE 94 Key Information – Lupin Limited
TABLE 95 key information – Astellas Pharma, Inc.
TABLE 96 Key Information – Glenmark Pharmaceuticals Limited
TABLE 97 Key Information – Boehringer Ingelheim International GmbH
TABLE 98 Key Information – Novartis AG
TABLE 99 Key Information – McKesson Corporation
TABLE 100 Key Information – GlaxoSmithKline PLC

List of Figures
FIG 1 Methodology for the research
FIG 2 LAMEA Diabetic Neuropathy Treatment Market, 2020 - 2031, USD Million
FIG 3 Key Factors Impacting Diabetic Neuropathy Treatment Market
FIG 4 Porter’s Five Forces Analysis – Diabetic Neuropathy Treatment Market
FIG 5 LAMEA Diabetic Neuropathy Treatment Market share by Distribution Channel, 2023
FIG 6 LAMEA Diabetic Neuropathy Treatment Market share by Distribution Channel, 2031
FIG 7 LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2031, USD Million
FIG 8 LAMEA Diabetic Neuropathy Treatment Market share by Drug Class, 2023
FIG 9 LAMEA Diabetic Neuropathy Treatment Market share by Drug Class, 2031
FIG 10 LAMEA Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2031, USD Million
FIG 11 LAMEA Diabetic Neuropathy Treatment Market share by Disorder Type, 2023
FIG 12 LAMEA Diabetic Neuropathy Treatment Market share by Disorder Type, 2031
FIG 13 LAMEA Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2031, USD Million
FIG 14 LAMEA Diabetic Neuropathy Treatment Market share by Country, 2023
FIG 15 LAMEA Diabetic Neuropathy Treatment Market share by Country, 2031
FIG 16 LAMEA Diabetic Neuropathy Treatment Market by Country, 2020 - 2031, USD Million
FIG 17 Recent strategies and developments: Abbott Laboratories
FIG 18 SWOT Analysis: Abbott Laboratories
FIG 19 Swot Analysis: Eli Lilly And Company
FIG 20 SWOT Analysis: Pfizer, Inc.
FIG 21 SWOT Analysis: Lupin Limited
FIG 22 SWOT Analysis: Astellas Pharma, Inc.
FIG 23 SWOT Analysis: Glenmark Pharmaceuticals Limited
FIG 24 SWOT Analysis: Boehringer Ingelheim International GmbH
FIG 25 SWOT Analysis: Novartis AG
FIG 26 SWOT Analysis: McKesson Corporation
FIG 27 SWOT Analysis: GlaxoSmithKline PLC